Salvage Regorafenib Emphasizes Need for Nuanced Treatment Selection in Metastatic CRC
October 9th 2021An expert from The University of Texas MD Anderson Cancer Center recently highlighted the ramifications of the phase 2 ReDOS trial, the need for molecular profiling in mCRC, and ongoing research on the combination of TKIs and checkpoint inhibitors.
Beauty and the Beast: The Two Faces of Nurse Preceptors
October 8th 2021Nursing students sometimes face surprising hostility from nurse preceptors, explains contributor, Serenity Mirabito. However, the best nurse preceptors operate as agents for good by training and fostering the enthusiasm of young nursing students.
Defining and Quantifying the Oncology Nurse Navigator Role
October 7th 2021Deidra Hamilton, MSN, RN, OCN, ONN-CG, recently presented on how cancer institutions can clearly define the role of a nurse navigator to prevent scope creep and use gap analysis and metrics to showcase the value of a navigator in their program.
Addressing COVID-19 Vaccine Hesitancy In BIPOC Patients with Cancer
October 6th 2021Answering questions without judgement and showcasing community members who have received the COVID-19 vaccine without negative outcomes can help alleiviate vaccine-related fears and concerns in BIPOC patients with cancer.
Families and Caregivers Can Help Protect Patients with Leukemia from COVID-19
October 5th 2021Stephanie Jackson, DNP, MSN, RN, AOCNS, BMTCN, Oncology Nursing News co-editor in chief, comments on the dedication she has observed from caregivers taking care of loved ones with leukemia during the COVID-19 era.
Expert Discusses Biggest Updates in NSCLC Treatment
October 1st 2021“I think the biggest [change] that we’ve seen is the addition of adjuvant or consolidated chemotherapy following the completion of concurrent chemotherapy and radiation. We have seen the 4-year overall survival data now and the 5-year update from the PACIFIC study in the adjuvant setting, obviously confirming the initial signal that patients who have initiation of immunotherapy early carry a significant risk reduction for progression and overall survival…”
FDA Approves Cetuximab Indication in Combination With Encorafenib to Treat Metastatic CRC Subtype
September 29th 2021Cetuximab represents the first approved anti-EGFR antibody which, in combination with encorafenib, is now available to treat adults with pretreated metastatic CRC with a BRAF V600E mutation.
Cannabis May Help Manage Cancer-Related Symptoms and AEs, But Clinical Research Remains a Challenge
September 27th 2021An expert weighs in on the advantages of cannabis treatment for patients with cancer, and how nurses can help patients navigate the cannabis-oncology space, in spite of certain research limitations.
Apalutamide Induces Impressive PSA Response and Solid Adherence Rates in Men with nmCRPC
September 23rd 2021Real-world evidence recently presented at the 2021 AUA Annual Meeting showed that high adherence rates and favorable prostate-specific antigen (PSA) response were observed in men with nmCRPC who were treated with apalutamide.